Arcus Biosciences, Inc. (RCUS)

As of 14 August 2026, short interest in RCUS is 13,848,822 shares, up 1,289,592 shares over the last month. Over the last 48 readings it ranged from 6,337,902 shares (15 October 2024) to 13,848,822 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 1.1M shares a day that is 12.3 days to cover, a crowded short.

<iframe src="https://xoomar.com/embed/stocks/rcus" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of RCUS volume is 11.8%, down 63.3 points over the last five sessions. Over the last 52 readings it ranged from 11.8% (11 September 2026) to 88.8% (16 July 2026). The latest reading sits at the bottom of that range. The latest reading is 40.9 points below the 30-session average of 52.7%, on 2.1M shares reported.

As of 11 August 2026, the fails-to-deliver balance in RCUS is 8 shares, down 107 shares over the last settlement date. Over the last 45 readings it ranged from 2 shares (14 July 2026) to 640,490 shares (11 June 2026). The latest reading sits at the bottom of that range.

Insiders at RCUS reported 8 open-market sells worth $3.0M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Azoy Alexander (Chief Accounting Officer) on 2026-08-21.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

1 Form 144 notice on file for RCUS worth $83K at the prices reported; 1 in the last 90 days worth $83K. Latest: ALEXANDER AZOY filed on 2026-08-21 to sell 2,827 shares ($83K) from 2026-08-21.

1 holder above 5% has filed on RCUS, 1 on Schedule 13D (active intent). The largest reported stake is Gilead Sciences, Inc. at 24.7% of the class (31,424,760 shares), filed 2026-08-07 for an event on 2026-08-05.

6 of the 30 tracked managers held RCUS at their latest 13F, $192.7M in total at quarter-end prices. Citadel Advisors is the largest at $97.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) Arcus Biosciences, Inc. reported revenue of $33.0M, up 312.5% from the same quarter a year earlier, and net loss of $91.0M (-0.72 diluted EPS). In FY 2025 it generated -$482.0M of operating cash flow. As of 2026-06-30, cash was $150.0M against $101.0M of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.